Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.